Ritter Pharmaceuticals | Therapeutic Treatments for Gastrointestinal Diseases

Management

Ritter Pharma has recruited and assembled an outstanding team of talented and experienced individuals with extensive big pharma & biotech experience.

Mr. Ritter has been studying the field of lactose intolerance for over 15 years, working and collaborating with leading experts from around the world.  As a result of this involvement, Mr. Ritter holds three patents and eight pending patents centered in this field. In 1997, he invented a prototype product to help reduce symptoms of lactose intolerance and then in 2004, he founded Ritter Pharmaceuticals, Inc.  In 2008 Mr. Ritter, along with his expert team embarked on a quest to develop a novel prescription treatment for lactose intolerance. The result of this effort established RP-G28, a therapeutic treatment which has the potential to become the first FDA-approved drug for treating symptoms of lactose intolerance.

Los Angeles Mayor Richard Riordan appointed Mr. Ritter to serve as a Los Angeles City Commissioner from 2000-2002. Mr. Ritter holds a bachelor’s degree in Political Science and a minor in Business from the University of Southern California. In addition, he graduated from Stanford Graduate School of Business’ Executive Education on Influence and Negotiation Strategies.

Mr. Ritter has extensive experience creating, building and managing diverse business enterprises. His success has been his ability to take ideas and grow major businesses. He currently serves as Chairman of Ritter Pharmaceuticals. In addition he provides corporate management, strategic planning and financial consulting for a wide range of market segments. In the health and beauty sector, Mr. Ritter was President and Vice-Chairman of Quality King Inc, the nation’s largest wholesale distributor for health care products with $5 billion in annual revenues (ranked the 18th largest privately held company, Forbes Top 100 List). Simultaneously, he worked as President and Chairman of Rockwood, a business he developed that produced private label HBA products for major national retailers including GNC and K-Mart. In the entertainment sector he served as Chairman of ON-TV, a division of Oak Industries (NYSE Company), where he managed the television division initiating exclusive broadcasts of Los Angeles, Chicago, and New York professional baseball, basketball, and hockey games. During 1980-1985, he produced the first televised home shopping program and directed development of the largest “pay-per-view” channel system for its time. In the personal services market, Mr. Ritter grew a people-to-people business, Elite Personal Search and Lifemates personal matchmaking service, in the U.S. and Canada. In the finance field, Mr Ritter served on the board of directors for the Martin Lawrence Art Galleries (NYSE Company). During his 20 years as a publisher, he produced monthly national consumer magazines including Playgirl. and released books that included It’s OK to Say No childrens’ series and Patti Regan Davis’ Homefront. Mr. Ritter also has a long history of public service that includes appointments by three Governors to several State of California Commissions, including eight years served as Commissioner on the California Prison Industry Authority. In 1981, Mr. Ritter was honored with the City of Hope’s Man of the Year award.

Ron is responsible for all aspects related to finances at Ritter Pharma. For the last ten years, Ron has worked as an independent consultant for numerous companies by assisting with banking, contracts, leases, operations, and strategic planning which include both private and public companies. Prior to starting his own company, Ron worked for KPMG, an international accounting firm, handling both public and private companies, financial reporting, and tax needs as well as numerous IPO’s. He also has thirty-nine years as a part-time professor teaching accounting at a number of colleges in the Los Angeles area. Ron received his Bachelor’s Degree and Master’s Degree in Accounting from the University of Arizona.

Dr. Good is a board certified gastroenterologist who has been practicing medicine for over 30 years. He is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. Dr. Good is nationally recognized for his clinical experience with clostridium difficile and has conducted extensive clinical research in many fields including biliary lipid metabolism, irritable bowel syndrome, and inflammatory bowel disease. He has published numerous abstracts and articles in various journals such as Gastroenterology and the American Journal of Gastroenterology. Additionally, he has over 20 years of experience serving on advisory boards for major pharmaceutical companies primarily focused on providing input towards the development of gastrointestinal treatments, including most notably rifaximin. Dr. Good received his M.D. from the Medical University of South Carolina, served his residency there, and was Chief Resident in Medicine. He was a Fellow in Gastroenterology at the University of Pennsylvania.

Mr. Jones has over 20 years of experience in a variety of roles at the interface between science and business. He has a broad therapeutic background in both biological and small molecule drugs and his positions have included work in business development, fund raising, operations, drug development, and licensing. Prior to joining Ritter Pharma, Mr. Jones worked as Chief Operating Officer at Sherrington Pharmaceuticals. In other positions, Mr. Jones has worked on clinical development programs, strategy and operations for startups, and in-licensing and out-licensing programs. Mr. Jones graduated from the University of Washington with a Ph.D. in Genetics and from Iowa State University with a B.S. in Biology/Biochemistry.

Ms. Campbell brings over 30 years of experience to Ritter Pharma, having held executive positions in the biotechnology, diagnostic, and pharmaceutical industries. In addition to being part of the Ritter Pharma team, Ms. Campbell is a senior partner for BioVirtue LLC, a company that provides executive and consulting services for the medical community. Prior to her work with BioVirtue, Ms. Campbell served as C.E.O. and C.O.O. at MicroPhage, a bacterial diagnostics firm, where she directed finance, research and development, product development, human resources, and clinical affairs. She has held other significant positions in the industry, including VP of Corporate Development at Myogen (now Gilead), General Manager of RPI/SiRNA (now Merck), Executive VP of ChemTrak, and VP of Hana Biologics. Ms. Campbell holds an MBA from the University of California, Berkeley.

Dr. Whitcomb offers extensive clinical trial management expertise to Ritter Pharma.  He was a founder and senior clinical research fellow at QuatRx Pharmaceuticals from 2000-2006 and currently serves as a consultant to multiple biotechnology companies. Formerly, he served in various management positions at Parke-Davis, the pharmaceutical division of Warner-Lambert, including vice president for clinical research and drug development. Prior to his tenure at Parke-Davis, he was on the faculty of the Harvard Medical School and an attending physician at Massachusetts General Hospital. Dr. Whitcomb has authored multiple scientific publications and is a member of numerous scientific and clinical organizations. He currently serves on the board of directors of Insmed, Incorporated.

Dr. Foyt oversees Ritter’s clinical development efforts as well as assists in building the Company’s overall infrastructure and management team. He brings extensive clinical and leadership experience to Ritter Pharma having spent the last seventeen years at major pharmaceutical companies. Prior to Ritter Pharma, Dr. Foyt served as Senior Vice President and Chief Medical Officer at Cebix, Inc. He previously was Vice President, Clinical Development at Metabasis Therapeutics, which he joined from Pfizer Global Research & Development where he served as Senior Director, Medical & Development Sciences and Therapy Area Site Head—Diabetes & Obesity. He began his industry career over fifteen years ago at Parke-Davis Pharmaceutical Research, Ann Arbor, MI where he was Director, Clinical Research, Endocrine and Metabolism prior to the acquisition of the company by Pfizer. He earned his medical degree in 1985 from Baylor College of Medicine where he also earned a Ph.D. in Cell Biology. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

Dick founded RG Johnson Pharmaceutical Consulting which focuses on Active Pharmaceutical Ingredient and finished dosage form production. He specializes in the areas of small molecule development and production, aseptic and sterile product production, and clinical global supply. Before founding his own company, Dick worked for Avera Pharmaceutical as the Vice President of Manufacturing where he was responsible for the development and manufacture of three acquired drug products from GSK, Lilly, and Novartis. He also successfully produced GMP drug substance and drug products approved by US and EU regulatory authorities for Phase 1 and 2 clinical trials. Dick’s 40 year history in manufacturing also includes Vice President of Imaging Operations at the Mallinckrodt Imaging Division of Tyco Healthcare. Dick received a BS in Chemical Engineering at the University of South Carolina and an MBA from East Carolina University.